<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02370602</url>
  </required_header>
  <id_info>
    <org_study_id>TAK-063_103</org_study_id>
    <secondary_id>U1111-1165-3362</secondary_id>
    <secondary_id>2012-004576-18</secondary_id>
    <nct_id>NCT02370602</nct_id>
  </id_info>
  <brief_title>An [^11C]T-773 Positron Emission Tomography (PET) Study to Determine Phosphodiesterase10A Occupancy by TAK-063</brief_title>
  <official_title>An Open-Label [^11C]T-773 Positron Emission Tomography Study to Determine Phosphodiesterase10A Occupancy by TAK-063 After a Single Oral Dose in Human Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to estimate phosphodiesterase 10A (PDE10A) occupancy in brain
      following a single dose of TAK-063.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The drug being tested in this study is called TAK-063. TAK-063 is was tested to estimate
      phosphodiesterase10A (PDE10A) occupancy in the brain following a single dose of TAK-063. This
      study used positron emission tomography (PET) scans to look at changes in the volume of
      tissue distribution before and after TAK-063 administration to calculate PDE10A occupancy in
      the brain.

      The study enrolled 13 participants. Participants were assigned to a treatment group based on
      an enrollment schedule. The first 4 participants were assigned to the Pilot Cohort and
      received one dose of TAK-063 30 mg or 1000 mg tablets. The remaining participants were
      enrolled into the Main Cohort and received one dose of TAK-063 at 3, 10, 30 or 100 mg.
      Participants in both cohorts also received 3 separate intravenous infusions of [^11C]T-773 &lt;8
      μg; 400MBq ± 10% followed by a PET scan.

      This single-centre trial was conducted in Sweden. The overall time to participate in this
      study was 46 days. Participants made 3 visits to the clinic, including one 3-day period of
      confinement to the clinic. Participants were contacted by phone on Day 16 for follow-up
      safety assessments.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phosphodiesterase 10A (PDE10A) Occupancy of Brain Regions With [^11C]T-773 at 3 Hours Following a Single Dose of TAK-063</measure>
    <time_frame>3 hours post-dose</time_frame>
    <description>Volume of tissue distribution (Vt) values will be estimated by several quantitative methods for each positron emission tomography (PET) scan. Based on the change in Vt before and after TAK-063 administration, PDE10A occupancy will be calculated. PET scan #2 in the Pilot Cohort and PET scan #1 in the Main Cohort will be used as a baseline for the occupancy calculation. Occupancy is reported for putamen only.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Phosphodiesterase 10A (PDE10A) Occupancy of Brain Regions With [^11C]T-773 at 23 Hours Following a Single Dose of TAK-063</measure>
    <time_frame>23 hours post-dose</time_frame>
    <description>Volume of tissue distribution (Vt) values will be estimated by several quantitative methods for each positron emission tomography (PET) scan. Based on the change in Vt before and after TAK-063 administration, PDE10A occupancy will be calculated. PET scan #2 in the Pilot Cohort and PET scan #1 in the Main Cohort will be used as a baseline for the occupancy calculation. Data was not available for participants in the pilot cohort. Occupancy is reported for putamen only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Experienced at Least 1 Treatment-Emergent Adverse Event</measure>
    <time_frame>First dose of study drug to 30 days after last dose of study drug (up to 46 days)</time_frame>
    <description>An adverse event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (eg, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. A treatment-emergent adverse event is defined as an adverse event with an onset that occurs after receiving study drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Markedly Abnormal Safety Laboratory Findings</measure>
    <time_frame>From Day 1 to Day 16</time_frame>
    <description>The percentage of participants with any markedly abnormal standard safety laboratory values was collected throughout study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Markedly Abnormal Vital Sign Measurements</measure>
    <time_frame>From Day 1 to Day 16</time_frame>
    <description>The percentage of participants with any markedly abnormal standard vital sign measurements was collected throughout study. BL=baseline. bpm=beats per minute.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Markedly Abnormal Criteria for Safety Electrocardiogram (ECG) Parameters</measure>
    <time_frame>From Day 1 to Day 16</time_frame>
    <description>The percentage of participants with any markedly abnormal standard 12-lead ECG measurements.
QTc - Bazett's Interval (msec) is ≥500 msec OR ≥30 msec change from Baseline and ≥450 msec</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax: Maximum Observed Plasma Concentration for TAK-063 and TAK-063 Metabolite M-I</measure>
    <time_frame>Pilot Cohort: Day 2 predose and at multiple time points (up to 24 hours) post-dose. Main Cohort: Day 1 predose and at multiple time points (up to 24 hours) post-dose.</time_frame>
    <description>Maximum observed plasma concentration (Cmax) is the peak plasma concentration of a drug after administration, obtained directly from the plasma concentration-time curve.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-063 and TAK-063 Metabolite M-I</measure>
    <time_frame>Pilot Cohort: Day 2 predose and at multiple time points (up to 24 hours) post-dose. Main Cohort: Day 1 predose and at multiple time points (up to 24 hours) post-dose.</time_frame>
    <description>Time to reach the maximum plasma concentration (Cmax), equal to time (hours) to Cmax.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC(0-tlqc): Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-063 and TAK-063 Metabolite M-I</measure>
    <time_frame>Pilot Cohort: Day 2 predose and at multiple time points (up to 24 hours) post-dose. Main Cohort: Day 1 predose and at multiple time points (up to 24 hours) post-dose.</time_frame>
    <description>(AUC(0-tlqc) is a measure of total plasma exposure to the drug from Time 0 to Time of the Last Quantifiable Concentration (AUC[0-tlqc]).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC(0-24): Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours Postdose for TAK-063 and TAK-063 Metabolite M-I</measure>
    <time_frame>Pilot Cohort: Day 2 predose and at multiple time points (up to 24 hours) post-dose. Main Cohort: Day 1 predose and at multiple time points (up to 24 hours) post-dose.</time_frame>
    <description>AUC(0-24) is a measure of total plasma exposure to the drug from Time 0 to 24 hours post-dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Plasma Concentration on Day 1 (Cavg) for TAK-063 and TAK-063 Metabolite M-I</measure>
    <time_frame>Pilot Cohort: Day 2 predose and at multiple time points (up to 24 hours) post-dose. Main Cohort: Day 1 predose and at multiple time points (up to 24 hours) post-dose.</time_frame>
    <description>Cavg is the average plasma concentration on Day 1, calculated as AUC(0-24)/24.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F: Oral Clearance of TAK-063</measure>
    <time_frame>Pilot Cohort: Day 2 predose and at multiple time points (up to 24 hours) post-dose. Main Cohort: Day 1 predose and at multiple time points (up to 24 hours) post-dose.</time_frame>
    <description>CL/F is apparent clearance of the drug from the plasma, calculated as the drug dose divided by area under the curve from time 0 to 24 hours post-dose, after multiple dosing (at steady state).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of TAK-063 Metabolite Cmax to TAK-063 Cmax</measure>
    <time_frame>Pilot Cohort: Day 2 predose and at multiple time points (up to 24 hours) post-dose. Main Cohort: Day 1 predose and at multiple time points (up to 24 hours) post-dose.</time_frame>
    <description>Cmax Ratio is the ratio of Cmax values of the metabolite compared to the parent calculated by dividing Cmax values of metabolite M-I with those of the parent drug TAK-063.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of TAK-063 Metabolite M-I AUC( 0-24) to TAK-063 AUC (0-24)</measure>
    <time_frame>Pilot Cohort: Day 2 predose and at multiple time points (up to 24 hours) post-dose. Main Cohort: Day 1 predose and at multiple time points (up to 24 hours) post-dose.</time_frame>
    <description>AUC Ratio is the ratio of AUC values of the metabolite compared to the parent calculated by dividing AUC values of metabolite M-I with those of the parent drug TAK-063.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC During the Positron Emission Tomography (PET) Scan Period (AUC(Scan)) at 3 Hours Post-dose for TAK-063 and TAK-063 Metabolite M-I</measure>
    <time_frame>3 hours post-dose</time_frame>
    <description>AUC values of TAK-063 and TAK-063 metabolite M-I during the PET scan at approximately 3 hours post TAK-063 administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cavg During the Positron Emission Tomography (PET) Scan Period (AUC(Scan)) at 3 Hours Post-dose for TAK-063 and TAK-063 Metabolite M-I</measure>
    <time_frame>3 hours post-dose</time_frame>
    <description>Cavg values of TAK-063 and TAK-063 metabolite M-I during the PET scan at approximately 3 hours post TAK-063 administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC During the Positron Emission Tomography (PET) Scan Period (AUC(Scan)) at 23 Hours Post-dose for TAK-063 and TAK-063 Metabolite M-I</measure>
    <time_frame>23 hours post-dose</time_frame>
    <description>AUC values of TAK-063 and TAK-063 metabolite M-I during the PET scan at approximately 23 hours post TAK-063 administration. Data was not available for participants in the pilot cohort.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cavg During the Positron Emission Tomography (PET) Scan Period (AUC(Scan)) at 23 Hours Post-dose for TAK-063 and TAK-063 Metabolite M-I</measure>
    <time_frame>23 hours post-dose</time_frame>
    <description>Cavg values of TAK-063 and TAK-063 metabolite M-I during the PET scan at approximately 23 hours post TAK-063 administration. Data is not available for the pilot cohort.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Pilot Cohort: [^11C]T-773 + TAK-063</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>[^11C]T-773 &lt;8 μg; 400MBq ± 10%, intravenous (IV), once on Days 1 and 2 prior to PET scans and TAK-063 30 mg or 1000 mg, tablets, orally, once on Day 2 and after PET scan #2 and prior to PET scan #3 and [^11C]T-773 IV after TAK-063 and prior to PET scan #3 on Day 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Main Cohort: TAK-063 + [^11C]T-773</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-063 3 to 100 mg, tablets, orally, once, on Day 1, and [^11C]T-773 &lt;8 μg; 400MBq ± 10%, intravenously (IV), prior to PET scans, twice on Day 1 (before and after administration of TAK-063) and once on Day 2 .</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAK-063</intervention_name>
    <description>TAK-063 tablets</description>
    <arm_group_label>Pilot Cohort: [^11C]T-773 + TAK-063</arm_group_label>
    <arm_group_label>Main Cohort: TAK-063 + [^11C]T-773</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[^11C]T-773</intervention_name>
    <description>[^11C]T-773 IV solution</description>
    <arm_group_label>Pilot Cohort: [^11C]T-773 + TAK-063</arm_group_label>
    <arm_group_label>Main Cohort: TAK-063 + [^11C]T-773</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Has never previously participated in a positron emission tomography (PET) study
             (lifetime).

          2. In the opinion of the investigator, the participant is capable of understanding and
             complying with protocol requirements.

          3. The participant, informed consent form and any required privacy authorization prior to
             the initiation of any study procedures.

          4. Is a healthy adult male, as determined by a physician based upon medical history and
             physical examination findings at Screening.

          5. Is aged 20 to 45 years, inclusive, at the time of informed consent.

          6. Weighs at least 50 kg and less than 100 kg and has a body mass index (BMI) between 18
             and 32 kg/m^2 inclusive at Screening.

          7. A male participant who is nonsterilized and sexually active with a female partner of
             childbearing potential agrees to use adequate contraception from signing of informed
             consent throughout the duration of the study and for 12 weeks after last dose.

          8. Has clinical laboratory evaluations (including clinical chemistry, hematology and
             complete urinalysis) within the reference range for the testing laboratory, unless the
             results are deemed not to be clinically significant (CS) by the investigator or
             sponsor at screening. Participants must have normal hemoglobin levels.

          9. Has a normal magnetic resonance imaging (MRI) scan or findings that are deemed not
             clinically significant at screening (the MRI scan may be performed on a day after
             other screening activities have been performed but before dosing).

        Exclusion Criteria:

          1. Has received any investigational compound within 90 days prior to Screening.

          2. Has received TAK-063 in a previous clinical study or as a therapeutic agent.

          3. Is an immediate family member, study site employee, or in a dependant relationship
             with a study site employee who is involved in the conduct of this study (eg, spouse,
             parent, child, sibling) or may consent under duress.

          4. Has uncontrolled, clinically significant neurologic, cardiovascular, pulmonary,
             hepatic, renal, metabolic, gastrointestinal, urologic, immunologic, endocrine disease,
             or psychiatric disorder, or other abnormality, which may impact the ability of the
             participant to participate or potentially confound the study results.

          5. Has a known hypersensitivity to any component of the formulation of TAK-063 or
             [^11C]T-773.

          6. Has a positive urine drug result for drugs of abuse or a positive breathalyzer test
             for alcohol at Screening or Day -1.

          7. Has a history of drug abuse (defined as any illicit drug use) or a history of alcohol
             abuse within 1 year prior to the screening visit or is unwilling to agree to abstain
             from alcohol until discharge from the Phase 1 unit and drugs throughout the study.

          8. Has taken any excluded medication, supplements, or food products listed in the
             Excluded Medications and Dietary Products table.

          9. Intends to donate sperm during the course of the study or within 12 weeks after last
             dose.

         10. Has evidence of current cardiovascular, central nervous system, hepatic, hematopoietic
             disease, renal dysfunction, metabolic or endocrine dysfunction, serious allergy,
             asthma hypoxemia, hypertension, seizures, or allergic skin rash. There is any finding
             in the participant's medical history, physical examination, or safety laboratory tests
             giving reasonable suspicion of a disease that would contraindicate taking TAK-063 or a
             similar drug in the same class, or that might interfere with the conduct of the study.
             This includes, but is not limited to, peptic ulcer disease, seizure disorders, and
             cardiac arrhythmias.

         11. The participant, in the opinion of the investigator, has current or recent (within 6
             months) gastrointestinal disease that would be expected to influence the absorption of
             drugs (ie, a history of malabsorption, esophageal reflux, peptic ulcer disease,
             erosive esophagitis frequent [more than once per week] occurrence of heartburn, or any
             surgical intervention [eg, cholecystectomy]).

         12. Has a history of cancer, except basal cell carcinoma which has been in remission for
             at least 5 years prior to Day 1.

         13. Has a positive test result for hepatitis B surface antigen (HBsAg), hepatitis C
             antibody (HCV), human immunodeficiency virus (HIV) antibody/antigen, at Screening.

         14. Has used nicotine-containing products (including but not limited to cigarettes, pipes,
             cigars, chewing tobacco, nicotine patch or nicotine gum) within 28 days prior to
             Check-In Day -1.

         15. Has poor peripheral arterial/venous access or recent arm or wrist trauma.

         16. Has donated or lost 450 mL or more of his blood volume (including plasmapheresis), or
             had a transfusion of any blood product within 3 months prior to Day 1.

         17. Has a Screening or Check-in (Day -1) abnormal (clinically significant)
             electrocardiogram (ECG).

         18. Has a supine blood pressure outside the ranges of 90 to 140 mm Hg for systolic and 50
             to 90 mm Hg for diastolic, if out of range may be repeated once for eligibility
             determination within a maximum of 5 minutes, at the Screening Visit or Check-in (Day
             -1).

         19. Has a resting heart rate outside the range 45 to 90 beats per minute (bpm), if out of
             range may be repeated once for eligibility determination within a maximum of 5
             minutes, at the Screening Visit or Check-in (Day -1).

         20. Has an increase in pulse of ≥30 beats per minute or an increase in pulse ≥120 beats
             per minute within 3 minutes of standing at Screening.

         21. Has a decrease of ≥20 mm Hg in systolic blood pressure or a decrease of ≥10 mm Hg in
             diastolic blood pressure within 3 minutes of standing at Screening.

         22. Has a QT interval with Fridericia correction method (QTcF) &gt;430 ms or PQ interval
             outside the range 120 to 220 ms, if out of range may be repeated once for eligibility
             determination within a maximum of 5 minutes, at the Screening Visit or Check-in (Day
             -1) Visit.

         23. Has abnormal Screening laboratory values that suggest a clinically significant
             underlying disease or participant with the following lab abnormalities: alanine
             aminotransferase (ALT) and/or aspartate aminotransferase (AST) &gt;1.5 the upper limits
             of normal.

         24. Has had administration of radioactive substances or exposure to significant radiation
             (eg, serial x-ray or computed tomography [CT] scans, barium meal) within the past 12
             months prior to Day 1 predose.

         25. Has any condition that would prevent an MRI from accurately or safely being performed
             (eg, claustrophobia, cardiac pacemaker, metallic implants or clips)

         26. Has any condition that would prevent the performance of a safe or accurate PET scan.

         27. Has any clinically significant MRI finding that in the opinion of the investigator
             would exclude the participant.

         28. Is unwilling to refrain from strenuous exercise from 120 hours before Check-in (Day
             -1) until discharge from the Phase 1 unit.

         29. Has a risk of suicide according to the Investigator's clinical judgment (eg, per
             Columbia-Suicide Severity Rating Scale (C-SSRS) or has made a suicide attempt in the
             previous 6 months.

         30. Has abnormal international normalized ratio (INR) or activated prothrombin time (aPTT)
             or other risk of bleeding disorder.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director Clinical Science</last_name>
    <role>Study Director</role>
    <affiliation>Takeda</affiliation>
  </overall_official>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 18, 2015</study_first_submitted>
  <study_first_submitted_qc>February 18, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 25, 2015</study_first_posted>
  <results_first_submitted>March 11, 2015</results_first_submitted>
  <results_first_submitted_qc>March 11, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 20, 2015</results_first_posted>
  <last_update_submitted>March 11, 2015</last_update_submitted>
  <last_update_submitted_qc>March 11, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 20, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Drug therapy</keyword>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants took part in the study at 1 investigative site in Sweden from 13 August 2013 to 12 March 2014.</recruitment_details>
      <pre_assignment_details>Healthy Volunteers received 1 of 5 treatments: 11C T-773,Tak-063 3 mg, Tak-063 10 mg, Tak-063 30 mg, Tak-063 100 mg or Tak-063 1000 mg.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>[^11C]T-773 Only</title>
          <description>[^11C]T-773 &lt;8 μg; 400MBq ± 10%, intravenous (IV), once on Days 1 and 2 only.</description>
        </group>
        <group group_id="P2">
          <title>TAK-063 3 mg + [^11C]T-773</title>
          <description>TAK-063 3 mg, tablets, orally, once, on Day 1, and [^11C]T-773 &lt;8 μg; 400MBq ± 10%, intravenously (IV), prior to PET scans, twice on Day 1 (before and after administration of TAK-063) and once on Day 2.</description>
        </group>
        <group group_id="P3">
          <title>TAK-063 10 mg + [^11C]T-773</title>
          <description>TAK-063 10 mg, tablets, orally, once, on Day 1, and [^11C]T-773 &lt;8 μg; 400MBq ± 10%, intravenously (IV), prior to PET scans, twice on Day 1 (before and after administration of TAK-063) and once on Day 2.</description>
        </group>
        <group group_id="P4">
          <title>TAK-063 30 mg + [^11C]T-773</title>
          <description>For main cohort, TAK-063 30 mg, tablets, orally, once, on Day 1, and [^11C]T-773 &lt;8 μg; 400MBq ± 10%, intravenously (IV), prior to PET scans, twice on Day 1 (before and after administration of TAK-063) and once on Day 2. For pilot cohort, TAK-063 30 mg, tablets, orally, once on Day 2, and [^11C]T-773 &lt;8 μg; 400MBq ± 10%, intravenously (IV), prior to PET scans, once on Day 1 (before and after administration of TAK-063) and twice on Day 2.</description>
        </group>
        <group group_id="P5">
          <title>TAK-063 100 mg + [^11C]T-773</title>
          <description>TAK-063 100 mg, tablets, orally, once, on Day 1, and [^11C]T-773 &lt;8 μg; 400MBq ± 10%, intravenously (IV), prior to PET scans, twice on Day 1 (before and after administration of TAK-063) and once on Day 2.</description>
        </group>
        <group group_id="P6">
          <title>TAK-063 1000 mg + [^11C]T-773</title>
          <description>TAK-063 1000 mg, tablets, orally, once, on Day 2, and [^11C]T-773 &lt;8 μg; 400MBq ± 10%, intravenously (IV), prior to PET scans, once on Day 1 and twice on Day 2 (before and after administration of TAK-063).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Pretreatment Event/Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>[^11C]T-773</title>
          <description>[^11C]T-773 &lt;8 μg; 400MBq ± 10%, intravenous (IV), once on Days 1 and 2 only.</description>
        </group>
        <group group_id="B2">
          <title>TAK-063 3 mg + [^11C]T-773</title>
          <description>TAK-063 3 mg, tablets, orally, once, on Day 1, and [^11C]T-773 &lt;8 μg; 400MBq ± 10%, intravenously (IV), prior to PET scans, twice on Day 1 (before and after administration of TAK-063) and once on Day 2.</description>
        </group>
        <group group_id="B3">
          <title>TAK-063 10 mg + [^11C]T-773</title>
          <description>TAK-063 10 mg, tablets, orally, once, on Day 1, and [^11C]T-773 &lt;8 μg; 400MBq ± 10%, intravenously (IV), prior to PET scans, twice on Day 1 (before and after administration of TAK-063) and once on Day 2.</description>
        </group>
        <group group_id="B4">
          <title>TAK-063 30 mg + [^11C]T-773</title>
          <description>For main cohort, TAK-063 30 mg, tablets, orally, once, on Day 1, and [^11C]T-773 &lt;8 μg; 400MBq ± 10%, intravenously (IV), prior to PET scans, twice on Day 1 (before and after administration of TAK-063) and once on Day 2. For pilot cohort, TAK-063 30 mg, tablets, orally, once on Day 2, and [^11C]T-773 &lt;8 μg; 400MBq ± 10%, intravenously (IV), prior to PET scans, once on Day 1 (before and after administration of TAK-063) and twice on Day 2.</description>
        </group>
        <group group_id="B5">
          <title>TAK-063 100 mg + [^11C]T-773</title>
          <description>TAK-063 100 mg, tablets, orally, once, on Day 1, and [^11C]T-773 &lt;8 μg; 400MBq ± 10%, intravenously (IV), prior to PET scans, twice on Day 1 (before and after administration of TAK-063) and once on Day 2.</description>
        </group>
        <group group_id="B6">
          <title>TAK-063 1000 mg + [^11C]T-773</title>
          <description>TAK-063 1000 mg, tablets, orally, once, on Day 2, and [^11C]T-773 &lt;8 μg; 400MBq ± 10%, intravenously (IV), prior to PET scans, once on Day 1 and twice on Day 2 (before and after administration of TAK-063).</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1"/>
            <count group_id="B2" value="2"/>
            <count group_id="B3" value="2"/>
            <count group_id="B4" value="3"/>
            <count group_id="B5" value="3"/>
            <count group_id="B6" value="2"/>
            <count group_id="B7" value="13"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24.0">Standard deviation can not be calculated for 1 participant.</measurement>
                    <measurement group_id="B2" value="27.5" spread="4.95"/>
                    <measurement group_id="B3" value="26.5" spread="0.71"/>
                    <measurement group_id="B4" value="37.7" spread="7.09"/>
                    <measurement group_id="B5" value="26.7" spread="3.51"/>
                    <measurement group_id="B6" value="27.0" spread="1.41"/>
                    <measurement group_id="B7" value="29.2" spread="6.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Sweden</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="183.0">Standard deviation can not be calculated for 1 participant.</measurement>
                    <measurement group_id="B2" value="180.5" spread="4.95"/>
                    <measurement group_id="B3" value="180.0" spread="1.41"/>
                    <measurement group_id="B4" value="178.0" spread="8.19"/>
                    <measurement group_id="B5" value="179.3" spread="7.51"/>
                    <measurement group_id="B6" value="177.0" spread="4.24"/>
                    <measurement group_id="B7" value="179.2" spread="5.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="83.00">Standard deviation can not be calculated for 1 participant.</measurement>
                    <measurement group_id="B2" value="76.40" spread="0.566"/>
                    <measurement group_id="B3" value="90.50" spread="4.950"/>
                    <measurement group_id="B4" value="85.90" spread="3.651"/>
                    <measurement group_id="B5" value="83.27" spread="15.938"/>
                    <measurement group_id="B6" value="80.65" spread="4.596"/>
                    <measurement group_id="B7" value="83.51" spread="8.233"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24.78">Standard deviation can not be calculated for 1 participant.</measurement>
                    <measurement group_id="B2" value="23.47" spread="1.117"/>
                    <measurement group_id="B3" value="27.92" spread="1.089"/>
                    <measurement group_id="B4" value="27.27" spread="3.267"/>
                    <measurement group_id="B5" value="25.86" spread="4.584"/>
                    <measurement group_id="B6" value="25.80" spread="2.701"/>
                    <measurement group_id="B7" value="26.04" spread="2.883"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Smoking Classification</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Never smoked</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Current smoker</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ex-smoker</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Phosphodiesterase 10A (PDE10A) Occupancy of Brain Regions With [^11C]T-773 at 3 Hours Following a Single Dose of TAK-063</title>
        <description>Volume of tissue distribution (Vt) values will be estimated by several quantitative methods for each positron emission tomography (PET) scan. Based on the change in Vt before and after TAK-063 administration, PDE10A occupancy will be calculated. PET scan #2 in the Pilot Cohort and PET scan #1 in the Main Cohort will be used as a baseline for the occupancy calculation. Occupancy is reported for putamen only.</description>
        <time_frame>3 hours post-dose</time_frame>
        <population>Pharmacodynamic Analysis Set includes all participants with data available for pharmacodynamic analysis..</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-063 3 mg + [^11C]T-773</title>
            <description>TAK-063 3 mg, tablets, orally, once, on Day 1, and [^11C]T-773 &lt;8 μg; 400MBq ± 10%, intravenously (IV), prior to PET scans, twice on Day 1 (before and after administration of TAK-063) and once on Day 2.</description>
          </group>
          <group group_id="O2">
            <title>TAK-063 10 mg</title>
            <description>TAK-063 10 mg, tablets, orally, once, on Day 1, and [^11C]T-773 &lt;8 μg; 400MBq ± 10%, intravenously (IV), prior to PET scans, twice on Day 1 (before and after administration of TAK-063) and once on Day 2.</description>
          </group>
          <group group_id="O3">
            <title>TAK-063 30 mg + [^11C]T-773</title>
            <description>For main cohort, TAK-063 30 mg, tablets, orally, once, on Day 1, and [^11C]T-773 &lt;8 μg; 400MBq ± 10%, intravenously (IV), prior to PET scans, twice on Day 1 (before and after administration of TAK-063) and once on Day 2. For pilot cohort, TAK-063 30 mg, tablets, orally, once on Day 2, and [^11C]T-773 &lt;8 μg; 400MBq ± 10%, intravenously (IV), prior to PET scans, once on Day 1 (before and after administration of TAK-063) and twice on Day 2.</description>
          </group>
          <group group_id="O4">
            <title>TAK-063 100 mg + [^11C]T-773</title>
            <description>TAK-063 100 mg, tablets, orally, once, on Day 1, and [^11C]T-773 &lt;8 μg; 400MBq ± 10%, intravenously (IV), prior to PET scans, twice on Day 1 (before and after administration of TAK-063) and once on Day 2.</description>
          </group>
          <group group_id="O5">
            <title>TAK-063 1000 mg + [^11C]T-773</title>
            <description>TAK-063 1000 mg, tablets, orally, once, on Day 2, and [^11C]T-773 &lt;8 μg; 400MBq ± 10%, intravenously (IV), prior to PET scans, once on Day 1 and twice on Day 2 (before and after administration of TAK-063).</description>
          </group>
        </group_list>
        <measure>
          <title>Phosphodiesterase 10A (PDE10A) Occupancy of Brain Regions With [^11C]T-773 at 3 Hours Following a Single Dose of TAK-063</title>
          <description>Volume of tissue distribution (Vt) values will be estimated by several quantitative methods for each positron emission tomography (PET) scan. Based on the change in Vt before and after TAK-063 administration, PDE10A occupancy will be calculated. PET scan #2 in the Pilot Cohort and PET scan #1 in the Main Cohort will be used as a baseline for the occupancy calculation. Occupancy is reported for putamen only.</description>
          <population>Pharmacodynamic Analysis Set includes all participants with data available for pharmacodynamic analysis..</population>
          <units>Percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.400" spread="16.4049"/>
                    <measurement group_id="O2" value="26.650" spread="2.4749"/>
                    <measurement group_id="O3" value="39.333" spread="11.1096"/>
                    <measurement group_id="O4" value="53.633" spread="0.9074"/>
                    <measurement group_id="O5" value="69.350" spread="3.8891"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phosphodiesterase 10A (PDE10A) Occupancy of Brain Regions With [^11C]T-773 at 23 Hours Following a Single Dose of TAK-063</title>
        <description>Volume of tissue distribution (Vt) values will be estimated by several quantitative methods for each positron emission tomography (PET) scan. Based on the change in Vt before and after TAK-063 administration, PDE10A occupancy will be calculated. PET scan #2 in the Pilot Cohort and PET scan #1 in the Main Cohort will be used as a baseline for the occupancy calculation. Data was not available for participants in the pilot cohort. Occupancy is reported for putamen only.</description>
        <time_frame>23 hours post-dose</time_frame>
        <population>Pharmacodynamic Analysis Set includes all participants with data available for pharmacodynamic analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-063 3 mg + [^11C]T-773</title>
            <description>TAK-063 3 mg, tablets, orally, once, on Day 1, and [^11C]T-773 &lt;8 μg; 400MBq ± 10%, intravenously (IV), prior to PET scans, twice on Day 1 (before and after administration of TAK-063) and once on Day 2.</description>
          </group>
          <group group_id="O2">
            <title>TAK-063 10 mg + [^11C]T-773</title>
            <description>TAK-063 10 mg, tablets, orally, once, on Day 1, and [^11C]T-773 &lt;8 μg; 400MBq ± 10%, intravenously (IV), prior to PET scans, twice on Day 1 (before and after administration of TAK-063) and once on Day 2.</description>
          </group>
          <group group_id="O3">
            <title>TAK-063 30 mg + [^11C]T-773</title>
            <description>For main cohort, TAK-063 30 mg, tablets, orally, once, on Day 1, and [^11C]T-773 &lt;8 μg; 400MBq ± 10%, intravenously (IV), prior to PET scans, twice on Day 1 (before and after administration of TAK-063) and once on Day 2. For pilot cohort, TAK-063 30 mg, tablets, orally, once on Day 2, and [^11C]T-773 &lt;8 μg; 400MBq ± 10%, intravenously (IV), prior to PET scans, once on Day 1 (before and after administration of TAK-063) and twice on Day 2.</description>
          </group>
          <group group_id="O4">
            <title>TAK-063 100 mg + [^11C]T-773</title>
            <description>TAK-063 100 mg, tablets, orally, once, on Day 1, and [^11C]T-773 &lt;8 μg; 400MBq ± 10%, intravenously (IV), prior to PET scans, twice on Day 1 (before and after administration of TAK-063) and once on Day 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Phosphodiesterase 10A (PDE10A) Occupancy of Brain Regions With [^11C]T-773 at 23 Hours Following a Single Dose of TAK-063</title>
          <description>Volume of tissue distribution (Vt) values will be estimated by several quantitative methods for each positron emission tomography (PET) scan. Based on the change in Vt before and after TAK-063 administration, PDE10A occupancy will be calculated. PET scan #2 in the Pilot Cohort and PET scan #1 in the Main Cohort will be used as a baseline for the occupancy calculation. Data was not available for participants in the pilot cohort. Occupancy is reported for putamen only.</description>
          <population>Pharmacodynamic Analysis Set includes all participants with data available for pharmacodynamic analysis.</population>
          <units>Percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.250" spread="0.7778"/>
                    <measurement group_id="O2" value="14.750" spread="1.7678"/>
                    <measurement group_id="O3" value="18.800">Standard deviation can not be calculated for 1 participant.</measurement>
                    <measurement group_id="O4" value="24.167" spread="18.6001"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Experienced at Least 1 Treatment-Emergent Adverse Event</title>
        <description>An adverse event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (eg, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. A treatment-emergent adverse event is defined as an adverse event with an onset that occurs after receiving study drug.</description>
        <time_frame>First dose of study drug to 30 days after last dose of study drug (up to 46 days)</time_frame>
        <population>Safety analysis set included all participants who received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>[^11C]T-773</title>
            <description>[^11C]T-773 &lt;8 μg; 400MBq ± 10%, intravenous (IV), once on Days 1 and 2 only.</description>
          </group>
          <group group_id="O2">
            <title>TAK-063</title>
            <description>TAK-063 3 to 1000 mg, tablets, orally, once, on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Experienced at Least 1 Treatment-Emergent Adverse Event</title>
          <description>An adverse event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (eg, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. A treatment-emergent adverse event is defined as an adverse event with an onset that occurs after receiving study drug.</description>
          <population>Safety analysis set included all participants who received at least one dose of study drug.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.5"/>
                    <measurement group_id="O2" value="75.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Markedly Abnormal Safety Laboratory Findings</title>
        <description>The percentage of participants with any markedly abnormal standard safety laboratory values was collected throughout study.</description>
        <time_frame>From Day 1 to Day 16</time_frame>
        <population>Safety analysis set included all participants who received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>[^11C]T-773</title>
            <description>[^11C]T-773 &lt;8 μg; 400MBq ± 10%, intravenous (IV), once on Days 1 and 2 only.</description>
          </group>
          <group group_id="O2">
            <title>TAK-063 3 mg + [^11C]T-773</title>
            <description>TAK-063 3 mg, tablets, orally, once, on Day 1, and [^11C]T-773 &lt;8 μg; 400MBq ± 10%, intravenously (IV), prior to PET scans, twice on Day 1 (before and after administration of TAK-063) and once on Day 2.</description>
          </group>
          <group group_id="O3">
            <title>TAK-063 10 mg + [^11C]T-773</title>
            <description>TAK-063 10 mg, tablets, orally, once, on Day 1, and [^11C]T-773 &lt;8 μg; 400MBq ± 10%, intravenously (IV), prior to PET scans, twice on Day 1 (before and after administration of TAK-063) and once on Day 2.</description>
          </group>
          <group group_id="O4">
            <title>TAK-063 30 mg + [^11C]T-773</title>
            <description>For main cohort, TAK-063 30 mg, tablets, orally, once, on Day 1, and [^11C]T-773 &lt;8 μg; 400MBq ± 10%, intravenously (IV), prior to PET scans, twice on Day 1 (before and after administration of TAK-063) and once on Day 2. For pilot cohort, TAK-063 30 mg, tablets, orally, once on Day 2, and [^11C]T-773 &lt;8 μg; 400MBq ± 10%, intravenously (IV), prior to PET scans, once on Day 1 (before and after administration of TAK-063) and twice on Day 2.</description>
          </group>
          <group group_id="O5">
            <title>TAK-063 100 mg + [^11C]T-773</title>
            <description>TAK-063 100 mg, tablets, orally, once, on Day 1, and [^11C]T-773 &lt;8 μg; 400MBq ± 10%, intravenously (IV), prior to PET scans, twice on Day 1 (before and after administration of TAK-063) and once on Day 2.</description>
          </group>
          <group group_id="O6">
            <title>TAK-063 1000 mg + [^11C]T-773</title>
            <description>TAK-063 1000 mg, tablets, orally, once, on Day 2, and [^11C]T-773 &lt;8 μg; 400MBq ± 10%, intravenously (IV), prior to PET scans, once on Day 1 and twice on Day 2 (before and after administration of TAK-063).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Markedly Abnormal Safety Laboratory Findings</title>
          <description>The percentage of participants with any markedly abnormal standard safety laboratory values was collected throughout study.</description>
          <population>Safety analysis set included all participants who received at least one dose of study drug.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="2"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Markedly Abnormal Vital Sign Measurements</title>
        <description>The percentage of participants with any markedly abnormal standard vital sign measurements was collected throughout study. BL=baseline. bpm=beats per minute.</description>
        <time_frame>From Day 1 to Day 16</time_frame>
        <population>Safety analysis set included all participants who received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>[^11C]T-773</title>
            <description>[^11C]T-773 &lt;8 μg; 400MBq ± 10%, intravenous (IV), once on Days 1 and 2 only.</description>
          </group>
          <group group_id="O2">
            <title>TAK-063 3 mg + [^11C]T-773</title>
            <description>TAK-063 3 mg, tablets, orally, once, on Day 1, and [^11C]T-773 &lt;8 μg; 400MBq ± 10%, intravenously (IV), prior to PET scans, twice on Day 1 (before and after administration of TAK-063) and once on Day 2.</description>
          </group>
          <group group_id="O3">
            <title>TAK-063 10 mg + [^11C]T-773</title>
            <description>TAK-063 10 mg, tablets, orally, once, on Day 1, and [^11C]T-773 &lt;8 μg; 400MBq ± 10%, intravenously (IV), prior to PET scans, twice on Day 1 (before and after administration of TAK-063) and once on Day 2.</description>
          </group>
          <group group_id="O4">
            <title>TAK-063 30 mg + [^11C]T-773</title>
            <description>For main cohort, TAK-063 30 mg, tablets, orally, once, on Day 1, and [^11C]T-773 &lt;8 μg; 400MBq ± 10%, intravenously (IV), prior to PET scans, twice on Day 1 (before and after administration of TAK-063) and once on Day 2. For pilot cohort, TAK-063 30 mg, tablets, orally, once on Day 2, and [^11C]T-773 &lt;8 μg; 400MBq ± 10%, intravenously (IV), prior to PET scans, once on Day 1 (before and after administration of TAK-063) and twice on Day 2.</description>
          </group>
          <group group_id="O5">
            <title>TAK-063 100 mg + [^11C]T-773</title>
            <description>TAK-063 100 mg, tablets, orally, once, on Day 1, and [^11C]T-773 &lt;8 μg; 400MBq ± 10%, intravenously (IV), prior to PET scans, twice on Day 1 (before and after administration of TAK-063) and once on Day 2.</description>
          </group>
          <group group_id="O6">
            <title>TAK-063 1000 mg + [^11C]T-773</title>
            <description>TAK-063 1000 mg, tablets, orally, once, on Day 2, and [^11C]T-773 &lt;8 μg; 400MBq ± 10%, intravenously (IV), prior to PET scans, once on Day 1 and twice on Day 2 (before and after administration of TAK-063).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Markedly Abnormal Vital Sign Measurements</title>
          <description>The percentage of participants with any markedly abnormal standard vital sign measurements was collected throughout study. BL=baseline. bpm=beats per minute.</description>
          <population>Safety analysis set included all participants who received at least one dose of study drug.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="2"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>During Treatment (tx) - &gt;Upper Cut-off</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>During tx - &lt;Lower Cut-off</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.5"/>
                    <measurement group_id="O2" value="50.0"/>
                    <measurement group_id="O3" value="50.0"/>
                    <measurement group_id="O4" value="33.3"/>
                    <measurement group_id="O5" value="66.7"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>During tx - Change Relative to BL Upper Criteria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.7"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="50.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>During tx - Change Relative to BL Lower Criteria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="50.0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>During tx - Overall</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.2"/>
                    <measurement group_id="O2" value="50.0"/>
                    <measurement group_id="O3" value="100.0"/>
                    <measurement group_id="O4" value="33.3"/>
                    <measurement group_id="O5" value="66.7"/>
                    <measurement group_id="O6" value="50.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pulse (bpm) - &gt;120 bpm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pulse (bpm) - &lt;50 bpm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.8"/>
                    <measurement group_id="O2" value="50.0"/>
                    <measurement group_id="O3" value="50.0"/>
                    <measurement group_id="O4" value="33.3"/>
                    <measurement group_id="O5" value="66.7"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pulse (bpm) - Increase of &gt;30 bpm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pulse (bpm) - Decrease of &gt;30 bpm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pulse (bpm) - Overall</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.8"/>
                    <measurement group_id="O2" value="50.0"/>
                    <measurement group_id="O3" value="50.0"/>
                    <measurement group_id="O4" value="33.3"/>
                    <measurement group_id="O5" value="66.7"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systolic Blood Pressure (mmHg) - &gt;180 mmHg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systolic Blood Pressure (mmHg) - &lt;85 mmHg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systolic Blood Pressure - Increase of &gt;40 mmHg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systolic Blood Pressure - Decrease of &gt;40 mmHg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systolic Blood Pressure (mmHg) - Overall</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic Blood Pressure (mmHg) - &gt;110 mmHg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic Blood Pressure (mmHg) - &lt;50 mmHg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic BP (mmHg) - Increase of &gt;20 mmHg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.7"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="50.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic BP (mmHg) - Decrease of &gt;20 mmHg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="50.0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic Blood Pressure (mmHg) - Overall</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.7"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="50.0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="50.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Temperature (Degree C) - &gt;37.7 C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Temperature (Degree C) - &lt;35.6 C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.7"/>
                    <measurement group_id="O2" value="50.0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Temperature (Degree C) - Overall</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.7"/>
                    <measurement group_id="O2" value="50.0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Markedly Abnormal Criteria for Safety Electrocardiogram (ECG) Parameters</title>
        <description>The percentage of participants with any markedly abnormal standard 12-lead ECG measurements.
QTc - Bazett's Interval (msec) is ≥500 msec OR ≥30 msec change from Baseline and ≥450 msec</description>
        <time_frame>From Day 1 to Day 16</time_frame>
        <population>Safety analysis set included all participants who received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>[^11C]T-773</title>
            <description>[^11C]T-773 &lt;8 μg; 400MBq ± 10%, intravenous (IV), once on Days 1 and 2 only.</description>
          </group>
          <group group_id="O2">
            <title>TAK-063 3 mg + [^11C]T-773</title>
            <description>TAK-063 3 mg, tablets, orally, once, on Day 1, and [^11C]T-773 &lt;8 μg; 400MBq ± 10%, intravenously (IV), prior to PET scans, twice on Day 1 (before and after administration of TAK-063) and once on Day 2.</description>
          </group>
          <group group_id="O3">
            <title>TAK-063 10 mg + [^11C]T-773</title>
            <description>TAK-063 10 mg, tablets, orally, once, on Day 1, and [^11C]T-773 &lt;8 μg; 400MBq ± 10%, intravenously (IV), prior to PET scans, twice on Day 1 (before and after administration of TAK-063) and once on Day 2.</description>
          </group>
          <group group_id="O4">
            <title>TAK-063 30 mg + [^11C]T-773</title>
            <description>For main cohort, TAK-063 30 mg, tablets, orally, once, on Day 1, and [^11C]T-773 &lt;8 μg; 400MBq ± 10%, intravenously (IV), prior to PET scans, twice on Day 1 (before and after administration of TAK-063) and once on Day 2. For pilot cohort, TAK-063 30 mg, tablets, orally, once on Day 2, and [^11C]T-773 &lt;8 μg; 400MBq ± 10%, intravenously (IV), prior to PET scans, once on Day 1 (before and after administration of TAK-063) and twice on Day 2.</description>
          </group>
          <group group_id="O5">
            <title>TAK-063 100 mg + [^11C]T-773</title>
            <description>TAK-063 100 mg, tablets, orally, once, on Day 1, and [^11C]T-773 &lt;8 μg; 400MBq ± 10%, intravenously (IV), prior to PET scans, twice on Day 1 (before and after administration of TAK-063) and once on Day 2.</description>
          </group>
          <group group_id="O6">
            <title>TAK-063 1000 mg + [^11C]T-773</title>
            <description>TAK-063 1000 mg, tablets, orally, once, on Day 2, and [^11C]T-773 &lt;8 μg; 400MBq ± 10%, intravenously (IV), prior to PET scans, once on Day 1 and twice on Day 2 (before and after administration of TAK-063).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Markedly Abnormal Criteria for Safety Electrocardiogram (ECG) Parameters</title>
          <description>The percentage of participants with any markedly abnormal standard 12-lead ECG measurements.
QTc - Bazett's Interval (msec) is ≥500 msec OR ≥30 msec change from Baseline and ≥450 msec</description>
          <population>Safety analysis set included all participants who received at least one dose of study drug.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="2"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Heart Rate (bpm) - &lt;50 bpm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.7"/>
                    <measurement group_id="O2" value="50.0"/>
                    <measurement group_id="O3" value="50.0"/>
                    <measurement group_id="O4" value="33.3"/>
                    <measurement group_id="O5" value="66.7"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Heart Rate (bpm) - Overall</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.7"/>
                    <measurement group_id="O2" value="50.0"/>
                    <measurement group_id="O3" value="50.0"/>
                    <measurement group_id="O4" value="33.3"/>
                    <measurement group_id="O5" value="66.7"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RR Interval (msec) - ≥1440 msec</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="33.3"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RR Interval (msec) - ≤600 msec</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RR Interval (msec) - Overall</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="33.3"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR Interval (msec) - ≥200 msec</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="33.3"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR Interval (msec) - ≤80 msec</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR Interval (msec) - Overall</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="33.3"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QRS Interval (msec) - ≥180 msec</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QRS Interval (msec) - ≤80 msec</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QRS Interval (msec) - Overall</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QT Interval (msec) - ≥460 msec</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="33.3"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QT Interval (msec) - &lt;280 msec</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QT Interval (msec) - Overall</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="33.3"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTc - Bazett's Interval (msec) - Overall</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTc - Fredericia's Interval (msec) - Overall</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cmax: Maximum Observed Plasma Concentration for TAK-063 and TAK-063 Metabolite M-I</title>
        <description>Maximum observed plasma concentration (Cmax) is the peak plasma concentration of a drug after administration, obtained directly from the plasma concentration-time curve.</description>
        <time_frame>Pilot Cohort: Day 2 predose and at multiple time points (up to 24 hours) post-dose. Main Cohort: Day 1 predose and at multiple time points (up to 24 hours) post-dose.</time_frame>
        <population>Pharmacokinetic Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-063 3 mg + [^11C]T-773</title>
            <description>TAK-063 3 mg, tablets, orally, once, on Day 1, and [^11C]T-773 &lt;8 μg; 400MBq ± 10%, intravenously (IV), prior to PET scans, twice on Day 1 (before and after administration of TAK-063) and once on Day 2.</description>
          </group>
          <group group_id="O2">
            <title>TAK-063 10 mg + [^11C]T-773</title>
            <description>TAK-063 10 mg, tablets, orally, once, on Day 1, and [^11C]T-773 &lt;8 μg; 400MBq ± 10%, intravenously (IV), prior to PET scans, twice on Day 1 (before and after administration of TAK-063) and once on Day 2.</description>
          </group>
          <group group_id="O3">
            <title>TAK-063 30 mg + [^11C]T-773</title>
            <description>For main cohort, TAK-063 30 mg, tablets, orally, once, on Day 1, and [^11C]T-773 &lt;8 μg; 400MBq ± 10%, intravenously (IV), prior to PET scans, twice on Day 1 (before and after administration of TAK-063) and once on Day 2. For pilot cohort, TAK-063 30 mg, tablets, orally, once on Day 2, and [^11C]T-773 &lt;8 μg; 400MBq ± 10%, intravenously (IV), prior to PET scans, once on Day 1 (before and after administration of TAK-063) and twice on Day 2.</description>
          </group>
          <group group_id="O4">
            <title>TAK-063 100 mg + [^11C]T-773</title>
            <description>TAK-063 100 mg, tablets, orally, once, on Day 1, and [^11C]T-773 &lt;8 μg; 400MBq ± 10%, intravenously (IV), prior to PET scans, twice on Day 1 (before and after administration of TAK-063) and once on Day 2.</description>
          </group>
          <group group_id="O5">
            <title>TAK-063 1000 mg + [^11C]T-773</title>
            <description>TAK-063 1000 mg, tablets, orally, once, on Day 2, and [^11C]T-773 &lt;8 μg; 400MBq ± 10%, intravenously (IV), prior to PET scans, once on Day 1 and twice on Day 2 (before and after administration of TAK-063).</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax: Maximum Observed Plasma Concentration for TAK-063 and TAK-063 Metabolite M-I</title>
          <description>Maximum observed plasma concentration (Cmax) is the peak plasma concentration of a drug after administration, obtained directly from the plasma concentration-time curve.</description>
          <population>Pharmacokinetic Analysis Set</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TAK-063</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.25" spread="3.323"/>
                    <measurement group_id="O2" value="22.78" spread="0.035"/>
                    <measurement group_id="O3" value="80.67" spread="35.147"/>
                    <measurement group_id="O4" value="77.05" spread="16.898"/>
                    <measurement group_id="O5" value="258.75" spread="18.031"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TAK-063 Metabolite M-I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.60" spread="7.637"/>
                    <measurement group_id="O2" value="19.65" spread="0.283"/>
                    <measurement group_id="O3" value="49.63" spread="18.393"/>
                    <measurement group_id="O4" value="80.43" spread="26.831"/>
                    <measurement group_id="O5" value="146.50" spread="10.607"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-063 and TAK-063 Metabolite M-I</title>
        <description>Time to reach the maximum plasma concentration (Cmax), equal to time (hours) to Cmax.</description>
        <time_frame>Pilot Cohort: Day 2 predose and at multiple time points (up to 24 hours) post-dose. Main Cohort: Day 1 predose and at multiple time points (up to 24 hours) post-dose.</time_frame>
        <population>Pharmacokinetic Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-063 3 mg + [^11C]T-773</title>
            <description>TAK-063 3 mg, tablets, orally, once, on Day 1, and [^11C]T-773 &lt;8 μg; 400MBq ± 10%, intravenously (IV), prior to PET scans, twice on Day 1 (before and after administration of TAK-063) and once on Day 2.</description>
          </group>
          <group group_id="O2">
            <title>TAK-063 10 mg + [^11C]T-773</title>
            <description>TAK-063 10 mg, tablets, orally, once, on Day 1, and [^11C]T-773 &lt;8 μg; 400MBq ± 10%, intravenously (IV), prior to PET scans, twice on Day 1 (before and after administration of TAK-063) and once on Day 2.</description>
          </group>
          <group group_id="O3">
            <title>TAK-063 30 mg + [^11C]T-773</title>
            <description>For main cohort, TAK-063 30 mg, tablets, orally, once, on Day 1, and [^11C]T-773 &lt;8 μg; 400MBq ± 10%, intravenously (IV), prior to PET scans, twice on Day 1 (before and after administration of TAK-063) and once on Day 2. For pilot cohort, TAK-063 30 mg, tablets, orally, once on Day 2, and [^11C]T-773 &lt;8 μg; 400MBq ± 10%, intravenously (IV), prior to PET scans, once on Day 1 (before and after administration of TAK-063) and twice on Day 2.</description>
          </group>
          <group group_id="O4">
            <title>TAK-063 100 mg + [^11C]T-773</title>
            <description>TAK-063 100 mg, tablets, orally, once, on Day 1, and [^11C]T-773 &lt;8 μg; 400MBq ± 10%, intravenously (IV), prior to PET scans, twice on Day 1 (before and after administration of TAK-063) and once on Day 2.</description>
          </group>
          <group group_id="O5">
            <title>TAK-063 1000 mg + [^11C]T-773</title>
            <description>TAK-063 1000 mg, tablets, orally, once, on Day 2, and [^11C]T-773 &lt;8 μg; 400MBq ± 10%, intravenously (IV), prior to PET scans, once on Day 1 and twice on Day 2 (before and after administration of TAK-063).</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-063 and TAK-063 Metabolite M-I</title>
          <description>Time to reach the maximum plasma concentration (Cmax), equal to time (hours) to Cmax.</description>
          <population>Pharmacokinetic Analysis Set</population>
          <units>hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TAK-063</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.25" spread="0.354"/>
                    <measurement group_id="O2" value="2.99" spread="0.018"/>
                    <measurement group_id="O3" value="1.33" spread="0.289"/>
                    <measurement group_id="O4" value="2.33" spread="0.563"/>
                    <measurement group_id="O5" value="2.25" spread="1.137"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TAK-063 Metabolite M-I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.50" spread="0.000"/>
                    <measurement group_id="O2" value="2.99" spread="0.018"/>
                    <measurement group_id="O3" value="1.64" spread="1.116"/>
                    <measurement group_id="O4" value="2.00" spread="0.000"/>
                    <measurement group_id="O5" value="2.79" spread="1.120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC(0-tlqc): Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-063 and TAK-063 Metabolite M-I</title>
        <description>(AUC(0-tlqc) is a measure of total plasma exposure to the drug from Time 0 to Time of the Last Quantifiable Concentration (AUC[0-tlqc]).</description>
        <time_frame>Pilot Cohort: Day 2 predose and at multiple time points (up to 24 hours) post-dose. Main Cohort: Day 1 predose and at multiple time points (up to 24 hours) post-dose.</time_frame>
        <population>Pharmacokinetic Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-063 3 mg + [^11C]T-773</title>
            <description>TAK-063 3 mg, tablets, orally, once, on Day 1, and [^11C]T-773 &lt;8 μg; 400MBq ± 10%, intravenously (IV), prior to PET scans, twice on Day 1 (before and after administration of TAK-063) and once on Day 2.</description>
          </group>
          <group group_id="O2">
            <title>TAK-063 10 mg + [^11C]T-773</title>
            <description>TAK-063 10 mg, tablets, orally, once, on Day 1, and [^11C]T-773 &lt;8 μg; 400MBq ± 10%, intravenously (IV), prior to PET scans, twice on Day 1 (before and after administration of TAK-063) and once on Day 2.</description>
          </group>
          <group group_id="O3">
            <title>TAK-063 30 mg + [^11C]T-773</title>
            <description>For main cohort, TAK-063 30 mg, tablets, orally, once, on Day 1, and [^11C]T-773 &lt;8 μg; 400MBq ± 10%, intravenously (IV), prior to PET scans, twice on Day 1 (before and after administration of TAK-063) and once on Day 2. For pilot cohort, TAK-063 30 mg, tablets, orally, once on Day 2, and [^11C]T-773 &lt;8 μg; 400MBq ± 10%, intravenously (IV), prior to PET scans, once on Day 1 (before and after administration of TAK-063) and twice on Day 2.</description>
          </group>
          <group group_id="O4">
            <title>TAK-063 100 mg + [^11C]T-773</title>
            <description>TAK-063 100 mg, tablets, orally, once, on Day 1, and [^11C]T-773 &lt;8 μg; 400MBq ± 10%, intravenously (IV), prior to PET scans, twice on Day 1 (before and after administration of TAK-063) and once on Day 2.</description>
          </group>
          <group group_id="O5">
            <title>TAK-063 1000 mg + [^11C]T-773</title>
            <description>TAK-063 1000 mg, tablets, orally, once, on Day 2, and [^11C]T-773 &lt;8 μg; 400MBq ± 10%, intravenously (IV), prior to PET scans, once on Day 1 and twice on Day 2 (before and after administration of TAK-063).</description>
          </group>
        </group_list>
        <measure>
          <title>AUC(0-tlqc): Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-063 and TAK-063 Metabolite M-I</title>
          <description>(AUC(0-tlqc) is a measure of total plasma exposure to the drug from Time 0 to Time of the Last Quantifiable Concentration (AUC[0-tlqc]).</description>
          <population>Pharmacokinetic Analysis Set</population>
          <units>ng*hr/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TAK-063</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.42" spread="5.795"/>
                    <measurement group_id="O2" value="318.56" spread="66.183"/>
                    <measurement group_id="O3" value="774.76" spread="127.644"/>
                    <measurement group_id="O4" value="897.17" spread="181.699"/>
                    <measurement group_id="O5" value="3288.62" spread="109.282"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TAK-063 Metabolite M-I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.74" spread="23.833"/>
                    <measurement group_id="O2" value="245.24" spread="30.128"/>
                    <measurement group_id="O3" value="519.92" spread="233.914"/>
                    <measurement group_id="O4" value="850.26" spread="325.161"/>
                    <measurement group_id="O5" value="1859.28" spread="308.436"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC(0-24): Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours Postdose for TAK-063 and TAK-063 Metabolite M-I</title>
        <description>AUC(0-24) is a measure of total plasma exposure to the drug from Time 0 to 24 hours post-dose.</description>
        <time_frame>Pilot Cohort: Day 2 predose and at multiple time points (up to 24 hours) post-dose. Main Cohort: Day 1 predose and at multiple time points (up to 24 hours) post-dose.</time_frame>
        <population>Pharmacokinetic Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-063 3 mg + [^11C]T-773</title>
            <description>TAK-063 3 mg, tablets, orally, once, on Day 1, and [^11C]T-773 &lt;8 μg; 400MBq ± 10%, intravenously (IV), prior to PET scans, twice on Day 1 (before and after administration of TAK-063) and once on Day 2.</description>
          </group>
          <group group_id="O2">
            <title>TAK-063 10 mg + [^11C]T-773</title>
            <description>TAK-063 10 mg, tablets, orally, once, on Day 1, and [^11C]T-773 &lt;8 μg; 400MBq ± 10%, intravenously (IV), prior to PET scans, twice on Day 1 (before and after administration of TAK-063) and once on Day 2.</description>
          </group>
          <group group_id="O3">
            <title>TAK-063 30 mg + [^11C]T-773</title>
            <description>For main cohort, TAK-063 30 mg, tablets, orally, once, on Day 1, and [^11C]T-773 &lt;8 μg; 400MBq ± 10%, intravenously (IV), prior to PET scans, twice on Day 1 (before and after administration of TAK-063) and once on Day 2. For pilot cohort, TAK-063 30 mg, tablets, orally, once on Day 2, and [^11C]T-773 &lt;8 μg; 400MBq ± 10%, intravenously (IV), prior to PET scans, once on Day 1 (before and after administration of TAK-063) and twice on Day 2.</description>
          </group>
          <group group_id="O4">
            <title>TAK-063 100 mg + [^11C]T-773</title>
            <description>TAK-063 100 mg, tablets, orally, once, on Day 1, and [^11C]T-773 &lt;8 μg; 400MBq ± 10%, intravenously (IV), prior to PET scans, twice on Day 1 (before and after administration of TAK-063) and once on Day 2.</description>
          </group>
          <group group_id="O5">
            <title>TAK-063 1000 mg + [^11C]T-773</title>
            <description>TAK-063 1000 mg, tablets, orally, once, on Day 2, and [^11C]T-773 &lt;8 μg; 400MBq ± 10%, intravenously (IV), prior to PET scans, once on Day 1 and twice on Day 2 (before and after administration of TAK-063).</description>
          </group>
        </group_list>
        <measure>
          <title>AUC(0-24): Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours Postdose for TAK-063 and TAK-063 Metabolite M-I</title>
          <description>AUC(0-24) is a measure of total plasma exposure to the drug from Time 0 to 24 hours post-dose.</description>
          <population>Pharmacokinetic Analysis Set</population>
          <units>ng*hr/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TAK-063</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.55" spread="5.348"/>
                    <measurement group_id="O2" value="324.98" spread="68.303"/>
                    <measurement group_id="O3" value="774.44" spread="129.997"/>
                    <measurement group_id="O4" value="910.12" spread="184.418"/>
                    <measurement group_id="O5" value="3289.62" spread="110.695"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TAK-063 Metabolite M-I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.64" spread="23.672"/>
                    <measurement group_id="O2" value="249.82" spread="31.357"/>
                    <measurement group_id="O3" value="519.82" spread="233.869"/>
                    <measurement group_id="O4" value="864.14" spread="332.414"/>
                    <measurement group_id="O5" value="1859.97" spread="309.411"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Average Plasma Concentration on Day 1 (Cavg) for TAK-063 and TAK-063 Metabolite M-I</title>
        <description>Cavg is the average plasma concentration on Day 1, calculated as AUC(0-24)/24.</description>
        <time_frame>Pilot Cohort: Day 2 predose and at multiple time points (up to 24 hours) post-dose. Main Cohort: Day 1 predose and at multiple time points (up to 24 hours) post-dose.</time_frame>
        <population>Pharmacokinetic Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-063 3 mg + [^11C]T-773</title>
            <description>TAK-063 3 mg, tablets, orally, once, on Day 1, and [^11C]T-773 &lt;8 μg; 400MBq ± 10%, intravenously (IV), prior to PET scans, twice on Day 1 (before and after administration of TAK-063) and once on Day 2.</description>
          </group>
          <group group_id="O2">
            <title>TAK-063 10 mg + [^11C]T-773</title>
            <description>TAK-063 10 mg, tablets, orally, once, on Day 1, and [^11C]T-773 &lt;8 μg; 400MBq ± 10%, intravenously (IV), prior to PET scans, twice on Day 1 (before and after administration of TAK-063) and once on Day 2.</description>
          </group>
          <group group_id="O3">
            <title>TAK-063 30 mg + [^11C]T-773</title>
            <description>For main cohort, TAK-063 30 mg, tablets, orally, once, on Day 1, and [^11C]T-773 &lt;8 μg; 400MBq ± 10%, intravenously (IV), prior to PET scans, twice on Day 1 (before and after administration of TAK-063) and once on Day 2. For pilot cohort, TAK-063 30 mg, tablets, orally, once on Day 2, and [^11C]T-773 &lt;8 μg; 400MBq ± 10%, intravenously (IV), prior to PET scans, once on Day 1 (before and after administration of TAK-063) and twice on Day 2.</description>
          </group>
          <group group_id="O4">
            <title>TAK-063 100 mg + [^11C]T-773</title>
            <description>TAK-063 100 mg, tablets, orally, once, on Day 1, and [^11C]T-773 &lt;8 μg; 400MBq ± 10%, intravenously (IV), prior to PET scans, twice on Day 1 (before and after administration of TAK-063) and once on Day 2.</description>
          </group>
          <group group_id="O5">
            <title>TAK-063 1000 mg + [^11C]T-773</title>
            <description>TAK-063 1000 mg, tablets, orally, once, on Day 2, and [^11C]T-773 &lt;8 μg; 400MBq ± 10%, intravenously (IV), prior to PET scans, once on Day 1 and twice on Day 2 (before and after administration of TAK-063).</description>
          </group>
        </group_list>
        <measure>
          <title>Average Plasma Concentration on Day 1 (Cavg) for TAK-063 and TAK-063 Metabolite M-I</title>
          <description>Cavg is the average plasma concentration on Day 1, calculated as AUC(0-24)/24.</description>
          <population>Pharmacokinetic Analysis Set</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TAK-063</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.86" spread="0.223"/>
                    <measurement group_id="O2" value="13.54" spread="2.846"/>
                    <measurement group_id="O3" value="32.27" spread="5.417"/>
                    <measurement group_id="O4" value="37.92" spread="7.684"/>
                    <measurement group_id="O5" value="137.07" spread="4.612"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TAK-063 Metabolite M-I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.74" spread="0.986"/>
                    <measurement group_id="O2" value="10.41" spread="1.307"/>
                    <measurement group_id="O3" value="21.66" spread="9.745"/>
                    <measurement group_id="O4" value="36.01" spread="13.851"/>
                    <measurement group_id="O5" value="77.50" spread="12.892"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CL/F: Oral Clearance of TAK-063</title>
        <description>CL/F is apparent clearance of the drug from the plasma, calculated as the drug dose divided by area under the curve from time 0 to 24 hours post-dose, after multiple dosing (at steady state).</description>
        <time_frame>Pilot Cohort: Day 2 predose and at multiple time points (up to 24 hours) post-dose. Main Cohort: Day 1 predose and at multiple time points (up to 24 hours) post-dose.</time_frame>
        <population>Pharmacokinetic Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-063 3 mg + [^11C]T-773</title>
            <description>TAK-063 3 mg, tablets, orally, once, on Day 1, and [^11C]T-773 &lt;8 μg; 400MBq ± 10%, intravenously (IV), prior to PET scans, twice on Day 1 (before and after administration of TAK-063) and once on Day 2.</description>
          </group>
          <group group_id="O2">
            <title>TAK-063 10 mg + [^11C]T-773</title>
            <description>TAK-063 10 mg, tablets, orally, once, on Day 1, and [^11C]T-773 &lt;8 μg; 400MBq ± 10%, intravenously (IV), prior to PET scans, twice on Day 1 (before and after administration of TAK-063) and once on Day 2.</description>
          </group>
          <group group_id="O3">
            <title>TAK-063 30 mg + [^11C]T-773</title>
            <description>For main cohort, TAK-063 30 mg, tablets, orally, once, on Day 1, and [^11C]T-773 &lt;8 μg; 400MBq ± 10%, intravenously (IV), prior to PET scans, twice on Day 1 (before and after administration of TAK-063) and once on Day 2. For pilot cohort, TAK-063 30 mg, tablets, orally, once on Day 2, and [^11C]T-773 &lt;8 μg; 400MBq ± 10%, intravenously (IV), prior to PET scans, once on Day 1 (before and after administration of TAK-063) and twice on Day 2.</description>
          </group>
          <group group_id="O4">
            <title>TAK-063 100 mg + [^11C]T-773</title>
            <description>TAK-063 100 mg, tablets, orally, once, on Day 1, and [^11C]T-773 &lt;8 μg; 400MBq ± 10%, intravenously (IV), prior to PET scans, twice on Day 1 (before and after administration of TAK-063) and once on Day 2.</description>
          </group>
          <group group_id="O5">
            <title>TAK-063 1000 mg + [^11C]T-773</title>
            <description>TAK-063 1000 mg, tablets, orally, once, on Day 2, and [^11C]T-773 &lt;8 μg; 400MBq ± 10%, intravenously (IV), prior to PET scans, once on Day 1 and twice on Day 2 (before and after administration of TAK-063).</description>
          </group>
        </group_list>
        <measure>
          <title>CL/F: Oral Clearance of TAK-063</title>
          <description>CL/F is apparent clearance of the drug from the plasma, calculated as the drug dose divided by area under the curve from time 0 to 24 hours post-dose, after multiple dosing (at steady state).</description>
          <population>Pharmacokinetic Analysis Set</population>
          <units>liter/hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.19" spread="1.099"/>
                    <measurement group_id="O2" value="18.31" spread="7.477"/>
                    <measurement group_id="O3" value="24.90" spread="2.209"/>
                    <measurement group_id="O4" value="88.86" spread="25.806"/>
                    <measurement group_id="O5" value="252.33" spread="21.971"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ratio of TAK-063 Metabolite Cmax to TAK-063 Cmax</title>
        <description>Cmax Ratio is the ratio of Cmax values of the metabolite compared to the parent calculated by dividing Cmax values of metabolite M-I with those of the parent drug TAK-063.</description>
        <time_frame>Pilot Cohort: Day 2 predose and at multiple time points (up to 24 hours) post-dose. Main Cohort: Day 1 predose and at multiple time points (up to 24 hours) post-dose.</time_frame>
        <population>Pharmacokinetic Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-063 3 mg + [^11C]T-773</title>
            <description>TAK-063 3 mg, tablets, orally, once, on Day 1, and [^11C]T-773 &lt;8 μg; 400MBq ± 10%, intravenously (IV), prior to PET scans, twice on Day 1 (before and after administration of TAK-063) and once on Day 2.</description>
          </group>
          <group group_id="O2">
            <title>TAK-063 10 mg + [^11C]T-773</title>
            <description>TAK-063 10 mg, tablets, orally, once, on Day 1, and [^11C]T-773 &lt;8 μg; 400MBq ± 10%, intravenously (IV), prior to PET scans, twice on Day 1 (before and after administration of TAK-063) and once on Day 2.</description>
          </group>
          <group group_id="O3">
            <title>TAK-063 30 mg + [^11C]T-773</title>
            <description>For main cohort, TAK-063 30 mg, tablets, orally, once, on Day 1, and [^11C]T-773 &lt;8 μg; 400MBq ± 10%, intravenously (IV), prior to PET scans, twice on Day 1 (before and after administration of TAK-063) and once on Day 2. For pilot cohort, TAK-063 30 mg, tablets, orally, once on Day 2, and [^11C]T-773 &lt;8 μg; 400MBq ± 10%, intravenously (IV), prior to PET scans, once on Day 1 (before and after administration of TAK-063) and twice on Day 2.</description>
          </group>
          <group group_id="O4">
            <title>TAK-063 100 mg + [^11C]T-773</title>
            <description>TAK-063 100 mg, tablets, orally, once, on Day 1, and [^11C]T-773 &lt;8 μg; 400MBq ± 10%, intravenously (IV), prior to PET scans, twice on Day 1 (before and after administration of TAK-063) and once on Day 2.</description>
          </group>
          <group group_id="O5">
            <title>TAK-063 1000 mg + [^11C]T-773</title>
            <description>TAK-063 1000 mg, tablets, orally, once, on Day 2, and [^11C]T-773 &lt;8 μg; 400MBq ± 10%, intravenously (IV), prior to PET scans, once on Day 1 and twice on Day 2 (before and after administration of TAK-063).</description>
          </group>
        </group_list>
        <measure>
          <title>Ratio of TAK-063 Metabolite Cmax to TAK-063 Cmax</title>
          <description>Cmax Ratio is the ratio of Cmax values of the metabolite compared to the parent calculated by dividing Cmax values of metabolite M-I with those of the parent drug TAK-063.</description>
          <population>Pharmacokinetic Analysis Set</population>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.30" spread="0.271"/>
                    <measurement group_id="O2" value="0.83" spread="0.013"/>
                    <measurement group_id="O3" value="0.65" spread="0.361"/>
                    <measurement group_id="O4" value="0.99" spread="0.145"/>
                    <measurement group_id="O5" value="0.55" spread="0.001"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ratio of TAK-063 Metabolite M-I AUC( 0-24) to TAK-063 AUC (0-24)</title>
        <description>AUC Ratio is the ratio of AUC values of the metabolite compared to the parent calculated by dividing AUC values of metabolite M-I with those of the parent drug TAK-063.</description>
        <time_frame>Pilot Cohort: Day 2 predose and at multiple time points (up to 24 hours) post-dose. Main Cohort: Day 1 predose and at multiple time points (up to 24 hours) post-dose.</time_frame>
        <population>Pharmacokinetic Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-063 3 mg + [^11C]T-773</title>
            <description>TAK-063 3 mg, tablets, orally, once, on Day 1, and [^11C]T-773 &lt;8 μg; 400MBq ± 10%, intravenously (IV), prior to PET scans, twice on Day 1 (before and after administration of TAK-063) and once on Day 2.</description>
          </group>
          <group group_id="O2">
            <title>TAK-063 10 mg + [^11C]T-773</title>
            <description>TAK-063 10 mg, tablets, orally, once, on Day 1, and [^11C]T-773 &lt;8 μg; 400MBq ± 10%, intravenously (IV), prior to PET scans, twice on Day 1 (before and after administration of TAK-063) and once on Day 2.</description>
          </group>
          <group group_id="O3">
            <title>TAK-063 30 mg + [^11C]T-773</title>
            <description>For main cohort, TAK-063 30 mg, tablets, orally, once, on Day 1, and [^11C]T-773 &lt;8 μg; 400MBq ± 10%, intravenously (IV), prior to PET scans, twice on Day 1 (before and after administration of TAK-063) and once on Day 2. For pilot cohort, TAK-063 30 mg, tablets, orally, once on Day 2, and [^11C]T-773 &lt;8 μg; 400MBq ± 10%, intravenously (IV), prior to PET scans, once on Day 1 (before and after administration of TAK-063) and twice on Day 2.</description>
          </group>
          <group group_id="O4">
            <title>TAK-063 100 mg + [^11C]T-773</title>
            <description>TAK-063 100 mg, tablets, orally, once, on Day 1, and [^11C]T-773 &lt;8 μg; 400MBq ± 10%, intravenously (IV), prior to PET scans, twice on Day 1 (before and after administration of TAK-063) and once on Day 2.</description>
          </group>
          <group group_id="O5">
            <title>TAK-063 1000 mg + [^11C]T-773</title>
            <description>TAK-063 1000 mg, tablets, orally, once, on Day 2, and [^11C]T-773 &lt;8 μg; 400MBq ± 10%, intravenously (IV), prior to PET scans, once on Day 1 and twice on Day 2 (before and after administration of TAK-063).</description>
          </group>
        </group_list>
        <measure>
          <title>Ratio of TAK-063 Metabolite M-I AUC( 0-24) to TAK-063 AUC (0-24)</title>
          <description>AUC Ratio is the ratio of AUC values of the metabolite compared to the parent calculated by dividing AUC values of metabolite M-I with those of the parent drug TAK-063.</description>
          <population>Pharmacokinetic Analysis Set</population>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.93" spread="0.193"/>
                    <measurement group_id="O2" value="0.75" spread="0.064"/>
                    <measurement group_id="O3" value="0.66" spread="0.357"/>
                    <measurement group_id="O4" value="0.89" spread="0.199"/>
                    <measurement group_id="O5" value="0.54" spread="0.072"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC During the Positron Emission Tomography (PET) Scan Period (AUC(Scan)) at 3 Hours Post-dose for TAK-063 and TAK-063 Metabolite M-I</title>
        <description>AUC values of TAK-063 and TAK-063 metabolite M-I during the PET scan at approximately 3 hours post TAK-063 administration.</description>
        <time_frame>3 hours post-dose</time_frame>
        <population>Pharmacokinetic Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-063 3 mg + [^11C]T-773</title>
            <description>TAK-063 3 mg, tablets, orally, once, on Day 1, and [^11C]T-773 &lt;8 μg; 400MBq ± 10%, intravenously (IV), prior to PET scans, twice on Day 1 (before and after administration of TAK-063) and once on Day 2.</description>
          </group>
          <group group_id="O2">
            <title>TAK-063 10 mg + [^11C]T-773</title>
            <description>TAK-063 10 mg, tablets, orally, once, on Day 1, and [^11C]T-773 &lt;8 μg; 400MBq ± 10%, intravenously (IV), prior to PET scans, twice on Day 1 (before and after administration of TAK-063) and once on Day 2.</description>
          </group>
          <group group_id="O3">
            <title>TAK-063 30 mg + [^11C]T-773</title>
            <description>For main cohort, TAK-063 30 mg, tablets, orally, once, on Day 1, and [^11C]T-773 &lt;8 μg; 400MBq ± 10%, intravenously (IV), prior to PET scans, twice on Day 1 (before and after administration of TAK-063) and once on Day 2. For pilot cohort, TAK-063 30 mg, tablets, orally, once on Day 2, and [^11C]T-773 &lt;8 μg; 400MBq ± 10%, intravenously (IV), prior to PET scans, once on Day 1 (before and after administration of TAK-063) and twice on Day 2.</description>
          </group>
          <group group_id="O4">
            <title>TAK-063 100 mg + [^11C]T-773</title>
            <description>TAK-063 100 mg, tablets, orally, once, on Day 1, and [^11C]T-773 &lt;8 μg; 400MBq ± 10%, intravenously (IV), prior to PET scans, twice on Day 1 (before and after administration of TAK-063) and once on Day 2.</description>
          </group>
          <group group_id="O5">
            <title>TAK-063 1000 mg + [^11C]T-773</title>
            <description>TAK-063 1000 mg, tablets, orally, once, on Day 2, and [^11C]T-773 &lt;8 μg; 400MBq ± 10%, intravenously (IV), prior to PET scans, once on Day 1 and twice on Day 2 (before and after administration of TAK-063).</description>
          </group>
        </group_list>
        <measure>
          <title>AUC During the Positron Emission Tomography (PET) Scan Period (AUC(Scan)) at 3 Hours Post-dose for TAK-063 and TAK-063 Metabolite M-I</title>
          <description>AUC values of TAK-063 and TAK-063 metabolite M-I during the PET scan at approximately 3 hours post TAK-063 administration.</description>
          <population>Pharmacokinetic Analysis Set</population>
          <units>ng*hr/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TAK-063</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.51" spread="1.217"/>
                    <measurement group_id="O2" value="25.68" spread="0.970"/>
                    <measurement group_id="O3" value="63.18" spread="13.667"/>
                    <measurement group_id="O4" value="82.25" spread="16.404"/>
                    <measurement group_id="O5" value="269.32" spread="23.429"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TAK-063 Metabolite M-I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.23" spread="3.850"/>
                    <measurement group_id="O2" value="22.56" spread="1.272"/>
                    <measurement group_id="O3" value="49.09" spread="21.273"/>
                    <measurement group_id="O4" value="85.13" spread="29.151"/>
                    <measurement group_id="O5" value="162.23" spread="6.527"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cavg During the Positron Emission Tomography (PET) Scan Period (AUC(Scan)) at 3 Hours Post-dose for TAK-063 and TAK-063 Metabolite M-I</title>
        <description>Cavg values of TAK-063 and TAK-063 metabolite M-I during the PET scan at approximately 3 hours post TAK-063 administration.</description>
        <time_frame>3 hours post-dose</time_frame>
        <population>Pharmacokinetic Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-063 3 mg + [^11C]T-773</title>
            <description>TAK-063 3 mg, tablets, orally, once, on Day 1, and [^11C]T-773 &lt;8 μg; 400MBq ± 10%, intravenously (IV), prior to PET scans, twice on Day 1 (before and after administration of TAK-063) and once on Day 2.</description>
          </group>
          <group group_id="O2">
            <title>TAK-063 10 mg + [^11C]T-773</title>
            <description>TAK-063 10 mg, tablets, orally, once, on Day 1, and [^11C]T-773 &lt;8 μg; 400MBq ± 10%, intravenously (IV), prior to PET scans, twice on Day 1 (before and after administration of TAK-063) and once on Day 2.</description>
          </group>
          <group group_id="O3">
            <title>TAK-063 30 mg + [^11C]T-773</title>
            <description>For main cohort, TAK-063 30 mg, tablets, orally, once, on Day 1, and [^11C]T-773 &lt;8 μg; 400MBq ± 10%, intravenously (IV), prior to PET scans, twice on Day 1 (before and after administration of TAK-063) and once on Day 2. For pilot cohort, TAK-063 30 mg, tablets, orally, once on Day 2, and [^11C]T-773 &lt;8 μg; 400MBq ± 10%, intravenously (IV), prior to PET scans, once on Day 1 (before and after administration of TAK-063) and twice on Day 2.</description>
          </group>
          <group group_id="O4">
            <title>TAK-063 100 mg + [^11C]T-773</title>
            <description>TAK-063 100 mg, tablets, orally, once, on Day 1, and [^11C]T-773 &lt;8 μg; 400MBq ± 10%, intravenously (IV), prior to PET scans, twice on Day 1 (before and after administration of TAK-063) and once on Day 2.</description>
          </group>
          <group group_id="O5">
            <title>TAK-063 1000 mg + [^11C]T-773</title>
            <description>TAK-063 1000 mg, tablets, orally, once, on Day 2, and [^11C]T-773 &lt;8 μg; 400MBq ± 10%, intravenously (IV), prior to PET scans, once on Day 1 and twice on Day 2 (before and after administration of TAK-063).</description>
          </group>
        </group_list>
        <measure>
          <title>Cavg During the Positron Emission Tomography (PET) Scan Period (AUC(Scan)) at 3 Hours Post-dose for TAK-063 and TAK-063 Metabolite M-I</title>
          <description>Cavg values of TAK-063 and TAK-063 metabolite M-I during the PET scan at approximately 3 hours post TAK-063 administration.</description>
          <population>Pharmacokinetic Analysis Set</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TAK-063</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.61" spread="0.974"/>
                    <measurement group_id="O2" value="20.54" spread="0.776"/>
                    <measurement group_id="O3" value="50.54" spread="10.934"/>
                    <measurement group_id="O4" value="65.80" spread="13.123"/>
                    <measurement group_id="O5" value="215.46" spread="18.743"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TAK-063 Metabolite M-I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.18" spread="3.080"/>
                    <measurement group_id="O2" value="18.05" spread="1.018"/>
                    <measurement group_id="O3" value="39.27" spread="17.018"/>
                    <measurement group_id="O4" value="68.10" spread="23.321"/>
                    <measurement group_id="O5" value="129.78" spread="5.222"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC During the Positron Emission Tomography (PET) Scan Period (AUC(Scan)) at 23 Hours Post-dose for TAK-063 and TAK-063 Metabolite M-I</title>
        <description>AUC values of TAK-063 and TAK-063 metabolite M-I during the PET scan at approximately 23 hours post TAK-063 administration. Data was not available for participants in the pilot cohort.</description>
        <time_frame>23 hours post-dose</time_frame>
        <population>Pharmacokinetic Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-063 3 mg + [^11C]T-773</title>
            <description>TAK-063 3 mg, tablets, orally, once, on Day 1, and [^11C]T-773 &lt;8 μg; 400MBq ± 10%, intravenously (IV), prior to PET scans, twice on Day 1 (before and after administration of TAK-063) and once on Day 2.</description>
          </group>
          <group group_id="O2">
            <title>TAK-063 10 mg + [^11C]T-773</title>
            <description>TAK-063 10 mg, tablets, orally, once, on Day 1, and [^11C]T-773 &lt;8 μg; 400MBq ± 10%, intravenously (IV), prior to PET scans, twice on Day 1 (before and after administration of TAK-063) and once on Day 2.</description>
          </group>
          <group group_id="O3">
            <title>TAK-063 30 mg + [^11C]T-773</title>
            <description>For main cohort, TAK-063 30 mg, tablets, orally, once, on Day 1, and [^11C]T-773 &lt;8 μg; 400MBq ± 10%, intravenously (IV), prior to PET scans, twice on Day 1 (before and after administration of TAK-063) and once on Day 2. For pilot cohort, TAK-063 30 mg, tablets, orally, once on Day 2, and [^11C]T-773 &lt;8 μg; 400MBq ± 10%, intravenously (IV), prior to PET scans, once on Day 1 (before and after administration of TAK-063) and twice on Day 2.</description>
          </group>
          <group group_id="O4">
            <title>TAK-063 100 mg + [^11C]T-773</title>
            <description>TAK-063 100 mg, tablets, orally, once, on Day 1, and [^11C]T-773 &lt;8 μg; 400MBq ± 10%, intravenously (IV), prior to PET scans, twice on Day 1 (before and after administration of TAK-063) and once on Day 2.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC During the Positron Emission Tomography (PET) Scan Period (AUC(Scan)) at 23 Hours Post-dose for TAK-063 and TAK-063 Metabolite M-I</title>
          <description>AUC values of TAK-063 and TAK-063 metabolite M-I during the PET scan at approximately 23 hours post TAK-063 administration. Data was not available for participants in the pilot cohort.</description>
          <population>Pharmacokinetic Analysis Set</population>
          <units>ng*hr/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TAK-063</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.75" spread="0.496"/>
                    <measurement group_id="O2" value="11.44" spread="4.243"/>
                    <measurement group_id="O3" value="21.22">Standard deviation can not be calculated for 1 participant.</measurement>
                    <measurement group_id="O4" value="21.15" spread="7.913"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TAK-063 Metabolite M-I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.43" spread="0.071"/>
                    <measurement group_id="O2" value="8.20" spread="2.631"/>
                    <measurement group_id="O3" value="19.96">Standard deviation can not be calculated for 1 participant.</measurement>
                    <measurement group_id="O4" value="22.97" spread="15.919"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cavg During the Positron Emission Tomography (PET) Scan Period (AUC(Scan)) at 23 Hours Post-dose for TAK-063 and TAK-063 Metabolite M-I</title>
        <description>Cavg values of TAK-063 and TAK-063 metabolite M-I during the PET scan at approximately 23 hours post TAK-063 administration. Data is not available for the pilot cohort.</description>
        <time_frame>23 hours post-dose</time_frame>
        <population>Pharmacokinetic Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-063 3 mg + [^11C]T-773</title>
            <description>TAK-063 3 mg, tablets, orally, once, on Day 1, and [^11C]T-773 &lt;8 μg; 400MBq ± 10%, intravenously (IV), prior to PET scans, twice on Day 1 (before and after administration of TAK-063) and once on Day 2.</description>
          </group>
          <group group_id="O2">
            <title>TAK-063 10 mg + [^11C]T-773</title>
            <description>TAK-063 10 mg, tablets, orally, once, on Day 1, and [^11C]T-773 &lt;8 μg; 400MBq ± 10%, intravenously (IV), prior to PET scans, twice on Day 1 (before and after administration of TAK-063) and once on Day 2.</description>
          </group>
          <group group_id="O3">
            <title>TAK-063 30 mg + [^11C]T-773</title>
            <description>For main cohort, TAK-063 30 mg, tablets, orally, once, on Day 1, and [^11C]T-773 &lt;8 μg; 400MBq ± 10%, intravenously (IV), prior to PET scans, twice on Day 1 (before and after administration of TAK-063) and once on Day 2. For pilot cohort, TAK-063 30 mg, tablets, orally, once on Day 2, and [^11C]T-773 &lt;8 μg; 400MBq ± 10%, intravenously (IV), prior to PET scans, once on Day 1 (before and after administration of TAK-063) and twice on Day 2.</description>
          </group>
          <group group_id="O4">
            <title>TAK-063 100 mg + [^11C]T-773</title>
            <description>TAK-063 100 mg, tablets, orally, once, on Day 1, and [^11C]T-773 &lt;8 μg; 400MBq ± 10%, intravenously (IV), prior to PET scans, twice on Day 1 (before and after administration of TAK-063) and once on Day 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Cavg During the Positron Emission Tomography (PET) Scan Period (AUC(Scan)) at 23 Hours Post-dose for TAK-063 and TAK-063 Metabolite M-I</title>
          <description>Cavg values of TAK-063 and TAK-063 metabolite M-I during the PET scan at approximately 23 hours post TAK-063 administration. Data is not available for the pilot cohort.</description>
          <population>Pharmacokinetic Analysis Set</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TAK-063</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.40" spread="0.397"/>
                    <measurement group_id="O2" value="9.15" spread="3.394"/>
                    <measurement group_id="O3" value="16.97">Standard deviation can not be calculated for 1 participant.</measurement>
                    <measurement group_id="O4" value="16.92" spread="6.331"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TAK-063 Metabolite M-</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.15" spread="0.056"/>
                    <measurement group_id="O2" value="6.56" spread="2.105"/>
                    <measurement group_id="O3" value="15.97">Standard deviation can not be calculated for 1 participant.</measurement>
                    <measurement group_id="O4" value="18.37" spread="12.735"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>First dose of study drug to 30 days after last dose of study drug (up to 46 days)</time_frame>
      <desc>At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.</desc>
      <group_list>
        <group group_id="E1">
          <title>[^11C]T-773</title>
          <description>[^11C]T-773 &lt;8 μg; 400MBq ± 10%, intravenous (IV), once on Days 1 and 2 only.</description>
        </group>
        <group group_id="E2">
          <title>TAK-063</title>
          <description>TAK-063 3 to 1000 mg, tablets, orally, once, on Day 1.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 16.0</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Infusion site pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Catheter site pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Infusion site erythema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Claustrophobia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Research Organization shall not publish any articles or papers nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data or insights from or any data, information or materials obtained or generated in the performance of its obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takeda’s sole discretion.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Director, Clinical Science</name_or_title>
      <organization>Takeda</organization>
      <phone>+1-877-825-3327</phone>
      <email>clinicaltrialregistry@tpna.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

